Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design.
暂无分享,去创建一个
Gianni Chessari | Brent Graham | Jose Cosme | Christopher W Murray | Miles Congreve | M. Congreve | C. Murray | G. Chessari | L. Fazal | R. Feltell | Donna M. Smith | A. Woodhead | M. Carr | R. McMenamin | M. O’Brien | G. Trewartha | A. Woolford | D. Rees | Andrew J Woodhead | Hayley Angove | Maria G Carr | Joseph E Coyle | Philip J Day | Robert Downham | Lynsey Fazal | Ruth Feltell | Eva Figueroa | Martyn Frederickson | Jonathan Lewis | Rachel McMenamin | M Alistair O'Brien | Lina Parra | Sahil Patel | Theresa Phillips | David C Rees | Sharna Rich | Donna-Michelle Smith | Gary Trewartha | Mladen Vinkovic | Brian Williams | Alison J-A Woolford | P. Day | S. Rich | J. Cosme | H. Angove | J. Coyle | Robert Downham | E. Figueroa | M. Frederickson | B. Graham | Sahil Patel | T. Phillips | M. Vinković | B. Williams | Jon Lewis | L. Parra | Brian Williams
[1] S. Lindquist,et al. HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.
[2] D. Wazer,et al. ErbB2 Degradation Mediated by the Co-chaperone Protein CHIP* , 2003, The Journal of Biological Chemistry.
[3] Giulio Rastelli,et al. Structure‐Based and in silico Design of Hsp90 Inhibitors , 2009, ChemMedChem.
[4] V. Cohn. Drug metabolism. , 2020, Advances in biology of skin.
[5] James R. Porter,et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. , 2006, Journal of medicinal chemistry.
[6] B. Blagg,et al. Hsp90 Inhibitors: Small Molecules that Transform the Hsp90 Protein Folding Machinery into a Catalyst for Protein Degradation. , 2006 .
[7] F. Hartl,et al. In Vivo Function of Hsp90 Is Dependent on ATP Binding and ATP Hydrolysis , 1998, The Journal of cell biology.
[8] Paul Workman,et al. Drugging the Cancer Chaperone HSP90 , 2007, Annals of the New York Academy of Sciences.
[9] X. Barril,et al. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. , 2009, Journal of Medicinal Chemistry.
[10] A. Beresford,et al. The metabolism and pharmacokinetics of amlodipine in humans and animals. , 1988, Journal of cardiovascular pharmacology.
[11] Jonathan Weissman,et al. Molecular Chaperones and Protein Quality Control , 2006, Cell.
[12] L. Pearl,et al. Structure and mechanism of the Hsp90 molecular chaperone machinery. , 2006, Annual review of biochemistry.
[13] L. Pearl,et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. , 2008, Cancer research.
[14] K. Bhalla,et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia , 2010, Leukemia.
[15] E Blanc,et al. Electronic Reprint Biological Crystallography Modelling Prior Distributions of Atoms for Macromolecular Refinement and Completion Roversi Et Al. ¯ Prior Distributions for Macromolecular Refinement and Completion , 2022 .
[16] C. Murray,et al. The rise of fragment-based drug discovery. , 2009, Nature chemistry.
[17] David J. Diller,et al. In Silico hERG Modeling: Challenges and Progress , 2009 .
[18] Gurmeet Kaur,et al. Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin , 2004, Clinical Cancer Research.
[19] M. Bermejo,et al. Pharmacokinetics in drug discovery. , 2008, Journal of pharmaceutical sciences.
[20] W Bruce Turnbull,et al. On the value of c: can low affinity systems be studied by isothermal titration calorimetry? , 2003, Journal of the American Chemical Society.
[21] B. Sigurskjold,et al. Exact analysis of competition ligand binding by displacement isothermal titration calorimetry. , 2000, Analytical biochemistry.
[22] Neal Rosen,et al. Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent , 1997, Cell.
[23] Martin K. Bayliss,et al. Pharmacokinetics and Metabolism in Drug Design , 2002 .
[24] Laura G. Dubois,et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. , 2009, Journal of medicinal chemistry.
[25] S. Jackson,et al. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives. , 2007, Journal of molecular biology.
[26] L. Fritz,et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.
[27] J. Lyons,et al. Biological characterization of AT 7519 , a small-molecule inhibitor of cyclin-dependent kinases , in human tumor cell lines , 2009 .
[28] Maurizio Recanatini,et al. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation , 2009, Expert opinion on drug metabolism & toxicology.
[29] L. Neckers,et al. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. , 2006, ACS chemical biology.
[30] Mike Wood,et al. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. , 2007, Journal of medicinal chemistry.
[31] William J Greenlee,et al. Dopamine D1/D5 receptor antagonists with improved pharmacokinetics: design, synthesis, and biological evaluation of phenol bioisosteric analogues of benzazepine D1/D5 antagonists. , 2005, Journal of medicinal chemistry.
[32] Holly McDonough,et al. CHIP: a link between the chaperone and proteasome systems , 2003, Cell stress & chaperones.
[33] Y. Janin. Heat Shock Protein 90 Inhibitors. A Text Book Example of Medicinal Chemistry , 2006 .
[34] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[35] Gianni Chessari,et al. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. , 2010, Journal of medicinal chemistry.
[36] A. Kuki,et al. Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. , 2002, Journal of medicinal chemistry.
[37] Sreenath V. Sharma,et al. Development of radicicol analogues. , 2003, Current cancer drug targets.
[38] L. Pearl,et al. Identification and Structural Characterization of the ATP/ADP-Binding Site in the Hsp90 Molecular Chaperone , 1997, Cell.
[39] Marcel L Verdonk,et al. Automated Protein–Ligand Crystallography for Structure‐Based Drug Design , 2006, ChemMedChem.
[40] K. Ballman,et al. P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response. , 2008, Cancer research.
[41] Roman A. Laskowski,et al. PDBsum: summaries and analyses of PDB structures , 2001, Nucleic Acids Res..
[42] L. Neckers,et al. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin , 1998, Cancer Chemotherapy and Pharmacology.
[43] P. Workman. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. , 2004, Cancer letters.
[44] P. Workman,et al. Death by chaperone: HSP90, HSP70 or both? , 2009, Cell cycle.
[45] U. Banerji,et al. Heat Shock Protein 90 as a Drug Target: Some Like It Hot , 2009, Clinical Cancer Research.
[46] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[47] Michael J Hartshorn,et al. AstexViewer: a visualisation aid for structure-based drug design. , 2002, Journal of computer-aided molecular design.
[48] G. Robertson,et al. HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.
[49] M. Sanguinetti,et al. A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.
[50] A. Kamal,et al. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90. , 2004, Journal of Medicinal Chemistry.
[51] Xiong Cai,et al. CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy , 2009, Clinical Cancer Research.
[52] M. Drysdale,et al. Medicinal chemistry of Hsp90 inhibitors. , 2008, Current topics in medicinal chemistry.
[53] B. Teicher. Tumor models for efficacy determination , 2006, Molecular Cancer Therapeutics.
[54] L. Neckers,et al. Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity , 2004, Investigational New Drugs.
[55] L. Pearl,et al. Expression and crystallization of the yeast Hsp82 chaperone, and preliminary x‐ray diffraction studies of the amino‐terminal domain , 1996, Proteins.
[56] R. Scannevin,et al. Heat shock protein 90: inhibitors in clinical trials. , 2010, Journal of medicinal chemistry.
[57] M. Bibby,et al. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.